Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
Quintiles has finally affixed a price tag to its long-held plans to go public, plotting to raise about $790 million and pay down its outstanding debt.
After scaling back its IPO price by about 85%, diagnostics outfit Cancer Genetics has some good news to report, pulling in $6.9 million once its under-writers exercised their over-allotment option.
Cancer Genetics was looking at a $41.9 million IPO when first it decided to go public last year, but now the company is seeking just $6 million in its initial offering, which it expects to close next week.
As the biotech advances its lead antiviral drug to Phase III development, Chimerix has tapped a veteran of one of the most high-profile pharma R&D programs in the world.
Cancer Genetics' target IPO price keeps on falling, from about to $41.9 million back in May to a hopeful $14.3 million now.
After besting rivals such as Oracle in the pharma market, Veeva Systems aims to complete an initial public offering that values the cloud software provider at $2 billion, sources told Bloomberg .
Last week's big news that Quintiles is finally going public left one burning question: How much will the company raise in its IPO?
AutoGenomics has given up on its second IPO less than 5 years after not having all of its paperwork together in time for a crucial regulatory filing deadline. But the California-based molecular diagnostics developer wants to make a third attempt in the second quarter of 2013.